As new treatments go under the spotlight at the American Society of Clinical Oncology meeting in Chicago, ImmunOs Therapeutics AG has concluded a healthy financing round to help advance its new class of biologics for cancer which it hopes will soon feature at the world's largest oncology conference.
The Swiss biotech has announced the closing of an oversubscribed series B financing round totalling $74m, led by new investors Samsara Biocapital, Lightspeed Venture Partners and Gimv
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?